Stability, Purity, and Safety Evaluation of MONOmolecule NMN Complex Utilizing HYGIEIA® Nicotinamide Mononucleotide
Author: Research & Development Division, MONOmolecule
Affiliations: Internal QC Laboratory, Independent Third‑Party Validation by SGS & Eurofins
Corresponding Contact: science@monomolecule.com
Date: January 2026
Abstract
This study evaluates the long-term stability, purity, and safety of β-Nicotinamide Mononucleotide (NMN) incorporated in MONOmolecule Golden Ratio 5-In-1 NAD+ Complex, sourced exclusively from HYGIEIA® raw material. The report consolidates multiple lines of analytical evidence—including high-precision high-performance liquid chromatography (HPLC), environmental stress stability studies, and third-party certifications by SGS, CTi, and Eurofins Laboratories—to validate the product’s compliance with FDA’s Good Manufacturing Practice (GMP) and ICH Q1A(R2) stability standards.
The HYGIEIA® NMN demonstrated superior chemical integrity, maintaining > 99.5 % purity across all accelerated and long-term test conditions (−15 °C, 25 °C, and 40 °C) for up to 24 months. Independent COA analyses confirmed 100.0 % NMN content, with non-detectable levels of heavy metals, pathogens, or organic contaminants.
1. Introduction
NMN’s molecular instability—particularly under high humidity, heat, and UV exposure—has historically challenged formulation fidelity and shelf-life claims across the dietary supplement industry. The MONOmolecule Golden Ratio 5-In-1 NAD+ Complex responds to this need by integrating HYGIEIA® β-NMN, a premium-grade NMN manufactured under ISO 9001 and ISO 17025-compliant quality systems, into a stability-optimized formulation. This dissertation report documents the compound’s validated purity, environmental durability, and safety under comprehensive test conditions in compliance with U.S. FDA 21 CFR Parts 111 and 211 and ICH Q1A(R2) guidelines.
2. Materials and Methods
2.1 Instrumentation and Test Design
The primary objective was to characterize the stability and purity retention of NMN under controlled temperature and humidity, simulating both real-world and accelerated degradation environments. Secondary objectives included the verification of microbiological and heavy-metal safety parameters.
- High-Performance Liquid Chromatography (HPLC) for quantitative purity analysis.
- ICH-Compliant Humidity & Temperature Chambers for environmental stability.
- Refrigerated and Accelerated Storage Units maintained at −15 °C, 25 °C / 75 % RH, and 40 °C / 75 % RH.
| Condition | Description | Duration | Purpose |
|---|---|---|---|
| Condition A | −15 °C sealed aluminum bag protection | 0–24 months | Long-term low-temperature storage |
| Condition B | 25 °C, 75 % RH sealed environment | 0–24 months | Real-time room-temperature storage |
| Condition C | 40 °C, 75 % RH (accelerated) sealed | 0–6 months | Accelerated degradation prediction |
3. Results
3.1 Purity Retention Across Conditions
| Temperature & Storage | Duration | Purity Range (%) |
|---|---|---|
| −15 °C (sealed) | 0 – 24 months | 99.48 – 99.71 |
| 25 °C (sealed, 75 % RH) | 0 – 24 months | 99.43 – 99.81 |
| 40 °C (accelerated 75 % RH) | 0 – 6 months | 99.46 – 99.81 |
These data confirm < 0.3 % variance in measured purity even under accelerated conditions, indicating extraordinary thermal and oxidative resistance. In contrast, conventional NMN grades frequently exhibit degradative loss exceeding 2–5 % within 12 months.
3.2 Physical and Independent Safety Verification
Across all environmental conditions, no significant color or textural changes were observed. Powder samples remained uniformly white and free-flowing. Independent certifications verify:
- SGS Analytical Report (2025-11-13): β-Nicotinamide Mononucleotide (β-NMN) content = 100.0 % via HPLC.
- Eurofins Analytical Report (2025-06-03): Heavy metals detected well below FDA limits (Lead 0.0688 mg/kg; Arsenic 0.0202 mg/kg; Cadmium < 0.002 mg/kg; Mercury < 0.001 mg/kg).
- Microbial Safety: Salmonella, Staphylococcus aureus, and coliforms not detected. Aerobic plate count < 10 cfu/g.
- Acute Oral Toxicity Assessment: Oral LD₅₀ > 5000 mg/kg, indicating non-toxic classification under OECD Guidelines.
4. Discussion
The sustained purity levels across −15 °C to 40 °C demonstrate the molecular stability of HYGIEIA® NMN, reflecting robust control over hygroscopicity and oxidative pathways. Comparative analysis indicates that HYGIEIA® NMN, as used in MONOmolecule, exceeds typical market averages by ~2–5 %, translating into higher bioefficacy and longer shelf stability. These findings meet or surpass specifications outlined in FDA 21 CFR 211.166 and ICH Q1A(R2).
Quality & Shipping FAQ
A: To ensure maximum molecular stability, we control our logistics from our climate-controlled Los Angeles warehouse. We provide worldwide shipping to ensure global access to pharmaceutical-grade NMN.
A: While standard NMN is heat-sensitive, our HYGIEIA® complex maintained >99.4% purity even at 104°F (40°C) for six months during accelerated stability testing.
Key References & Clinical Literature
- Nat. Rev. Mol. Cell Biol., 2021. "NAD⁺ metabolism and its roles in cellular processes during ageing." — Covarrubias AJ, et al.
- Cell Metab., 2018. "NAD⁺ intermediates: the biology and therapeutic potential of NMN and NR." — Yoshino J, Baur JA, Imai SI.
- Science, 2021. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." — Yoshino M, et al.
- npj Aging, 2022. "Nicotinamide mononucleotide supplementation improves physical function in healthy older men." — Igarashi M, et al.
- GeroScience, 2024. "Ingestion of β-nicotinamide mononucleotide increased blood NAD levels and improved sleep quality in older adults." — Kim M, et al.
- Nature Communications, 2018. "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD⁺ in healthy middle-aged and older adults." — Martens CR, et al.
- J. Biol. Chem., 2010. "PQQ Stimulates Mitochondrial Biogenesis through CREB Phosphorylation." — Landmark mechanistic study.
- Nat. Metab., 2019. "Slc12a8 is a nicotinamide mononucleotide transporter." — Grozio A, et al.
- Metabolites, 2024. "NMN Supplementation: Understanding Metabolic Variability and Clinical Implications." — Poddar SK, et al.
- Pharmacological Research, 2020. "The Science Behind NMN—A Stable, Reliable NAD+ Activator." — Shade C.
© 2026 MONOmolecule R&D Division. Stability data verified by SGS, Eurofins, and CTi. Not medical advice.
